ARID1A and neoplasm: Specifically, the relationship between ARID1A loss/mutation, clinical characteristics, outcomes, CD8+ tumor-infiltrating lymphocytes (CD8+TIL), and DNA mismatch repair deficiency (MMRD) revealed ARID1A gene inactivation in 42% of OCCC and 25% of OEC.